Clearside Biomedical Inc (CLSD) Directors and Executive Officers

Officers & Directors

Charles A. Deignan
Chief Financial Officer - (Principal Financial Officer and Principal Accounting Officer)

Richard Croarkin
Director

Clay B. Thorp
Director

Jeffrey L. Edwards
Director

William D. Humphries
Director

George Lasezkay, Pharm.D., J.D.
President, Chief Executive Officer and Director - (Principal Executive Officer)

Nancy J. Hutson
Director

Benjamin R. Yerxa
Director

Christy L. Shaffer, Ph.D.
Director ,

Clearside Biomedical Inc currently has 32 employees.

News about Clearside Biomedical Inc Key Personnel

Clearside Biomedical Appoints Ophthalmology Expert Dr. Glenn Yiu to Scientific Advisory Board Amidst Challenging Financial Results

Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS), has announced the appointment of Glenn C. Yiu, M.D., Ph.D., as a new member of its Scientific Advisory Board (SAB). The SAB consists of renowned retinal physicians within the industry, providing valuable medical and scientific expertise for the company s research and development programs.
Dr. Yiu currently holds the position of Professor of Ophthalmology at the University of California, Davis. His extensive knowledge and experience in ophthalmology make him a valuable addition to Clearside Biomedical s SAB. He will bring valuable i...

Exploring the Pioneering Frontier of Suprachoroidal Drug Delivery: Clearside Biomedical's Virtual KOL Event Sheds Light on the Future of Ocular Therapies

C...

Clearside Biomedical Appoints Chief Medical Officer with Extensive Retinal Disease Research Background Amidst Financial Struggles

Clearside Biomedical Inc, a biopharmaceutical company specializing in retinal disease research and clinical development, recently announced the appointment of Victor Chong, M.D., MBA as their Chief Medical Officer. Dr. Chong brings with him a wealth of experience and a proven track record in advancing programs through clinical development, making him a valuable addition to the company s leadership team. However, this news comes in the backdrop of Clearside Biomedical recording a significant net loss and negative return on investment in the last year.
According to the financial reports, Clearside Biomedical Inc reported a cumulative net loss of -$37 million during the 12 months ending in the thi...